Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all 
Introduction
Worldwide, almost 200,000 patients are diagnosed with cutaneous melanoma (melanoma) each year [1] . Incidence rates are increasing in all countries, except in Australia and Canada [2] . Although, incidence rates in Australia remain very high. In the Netherlands the incidence of melanoma increased since 1989, the first year of the National Cancer Registry. Incidence, mortality and survival of cutaneous melanoma in the Netherlands were described by de Vries et al. up to 1998 [3] . Ten years of additional data have become available since these analyses.
Incidence of all cutaneous malignancies in the Netherlands have recently been described by Holterhues et al., indicating that melanoma incidence has almost doubled in 2005 compared to 1989 [4] . As melanoma incidence rates are rising in many countries, it is debated if this increase represents a real melanoma epidemic or that this might have been caused by increased awareness leading to potential overdiagnosis. Overdiagnosis in melanoma could be the results of diagnostic drift, which reclassified what were previously found to be benign melanocytic nevi as truly malignant melanomas [5] [6] [7] . We hypothesized that there is a real increase in melanoma incidence and that, therefore, there is a real increase in thin and thick melanomas as well as melanoma related mortality. To examine this controversy in the Netherlands, incidence rates together with mortality rates and survival of melanoma patients were examined to better understand the recent trends of melanoma in the general Dutch population.
Methods

Data collection
Population-based data from the nationwide Netherlands Cancer Registry (NCR), which started in 1989 and is maintained and hosted by the Comprehensive Cancer Centres, were used [8] . The NCR is based on notification of all newly diagnosed malignancies in the Netherlands by the automated pathological archive (PALGA). Additional sources are the national registry of hospital discharge, which accounts up to 8% of new cases, haematology departments and radiotherapy institutions. Information on patient characteristics like sex, date of birth, and tumour characteristics such as date of diagnosis, subsite (International Classification of Diseases for Oncology (ICD-O-3) [9] histology, stage (Tumour Lymph Node Metastasis (TNM) classification) [10] are obtained routinely from the medical records. The quality of the data is high, due to thorough training of the administrators and computerised consistency checks at regional and national levels. Completeness is estimated to be at least 95%. Follow-up of vital status of all patients was calculated as the time from diagnosis to death or to the 1st of February 2010. The information on vital status was initially obtained from municipal registries and from 1995 onwards from the nationwide population registries network. These registries provide virtually complete coverage of all deceased Dutch citizens.
For the present study, all patients with invasive primary cutaneous melanoma (C43) diagnosed in the period 1989-2008 in the Netherlands were included (n=45,919). Age was divided in three groups (0-44, 45-64, ≥65years). The study period was divided in four categories: 1989-1993, 1994-1998, 1999-2003, and 2004-2008 Traditional cohort-based 10-year relative survival analysis was used for the period 1989-1998 which represents the survival of patients diagnosed during 1989-1998. Since follow-up was available until January 2010 period-based 10-year relative survival analysis was used for the most recent period 1999-2008, which gives the most up-to-date estimates for this period [11] .
Multivariate relative survival analyses, using Poisson regression modeling, were carried out to estimate relative excess risk (RER) of dying adjusted for follow-up interval [12] . Two multivariate models were fit; a model without Breslow thickness, covering the whole period 
Results
The average population size of the Netherlands between 1989 and 2008 was 15.7 million.
During this 20-year period 19,393 males and 26,526 females were diagnosed with melanoma.
Between 1989 and 2009 5,840 males and 4,769 females died due to melanoma.
Trends in incidence
The age-standardised incidence (ESR per 100,000 person-years) increased from 11. was the most commonly diagnosed subtype in males and females and the incidence of this subtype increased more rapidly than the incidence of other subtypes (EAPC 7.6, 95% CI: 7.1-8.2 and 6.5, 95%CI: 6.0-7.0 for males and females, respectively). The trunk was the most commonly affected body site in males and the legs were the most commonly affected body site in females.
The incidence of melanoma in each of the 4 Breslow thickness categories increased significantly in the study period. Thin melanomas (<= 1mm) increased each year with 7.0% and 6.1% for males and females, respectively. Thick melanomas (>4 mm) increased as well,
with an annual increase of 5.3% for males and 6.5% for females. Thick melanomas increased with approximately the same rate as thin melanomas in females. In contrast to Breslow thickness and nodal involvement, the presence of systemic metastasis did not increase significantly between 1989 and 2008.
Trends in survival
Over time, a small increase in relative survival was observed for both sexes [ Table 2 , Figure   2 ]. The 10-year relative survival for males increased significantly from 70% in the period 1989-1993 to 77% in the period 2004-2008 (p < 0.001). In the same period, the 10-year relative survival for females increased significantly from 85% to 88% (p < 0.01). The relative excess risk (RER) of dying decreased significantly over time for males and females [ Table 2 ].
Relative survival improved significantly in more recent periods of diagnosis, also after adjusting for age, histological subtype, bodysite, nodular status, metastatic status and Breslow thickness. Relative excess risks showed the expected patterns for all mentioned covariates [ 
Trends in mortality
The absolute number of annual deaths due to melanoma increased from 337 in 1989 to 794 in 2009. The age-standardised mortality rate due to melanoma increased from 2.2 per 100,000
person years in 1989 to 3.9 per 100,000 person years in 2009 (EAPC 2.3, 95% CI: 2.0-2.6)
[ Figure 1 ]. Mortality rates in younger patients (0-44 year) remained stable over the years [ Figure 3 ]. A significant increase in mortality was observed in patients aged 45 to 64 years.
The steepest increase in mortality was observed in males and females older than 65 years (EAPC 4.1, 95% CI: 3.1-5.0 and 2.2, 95% CI: 1.4-3.0, respectively).
Discussion
The aim of our study was to assess concordance in time in trends of incidence, mortality and survival of cutaneous melanoma in the Dutch general population. The findings of this study suggest that the melanoma incidence is truly rising and is not solely depending on increased diagnosis, because melanoma incidence among all Breslow categories increased as well as melanoma mortality.
Trends in incidence
An overall increase in incidence rate was observed, which is in line with results from many countries [2, [13] [14] [15] . However, in Australia and Canada incidence rates have been observed to be stabilizing or even decreasing in younger individuals [16] [17] , possibly as result of successful health care campaigns in avoiding sun exposure [17] . In most countries the increase in incidence rate is primarily due to an increase of thin melanomas while the incidence rate of thick melanomas is no longer increasing [18] [19] . It has been debated that this epidemiologic pattern indicates early diagnosis due to improved awareness and possibly overdiagnosis by pathologists rather than a real increase in the disease.
We observed an increase in thin as well as thick (>4 mm) melanomas. In females, the thick melanomas increased annually with the same percentage as thin melanomas. Similar results are reported in England and the USA among older patients (>65 years) [13, 15] . The observed increase over the whole spectrum of all stages of melanoma is an argument in favor of a real increase in incidence of disease [7] . Alternative explanations would include a more conservative approach of the pathologists or improvements in the cancer registry practices.
The more conservative pathologist explanation would mainly result in increases in the thin melanomas. It is possible that the cancer registry has improved over time, resulting in a larger proportion of melanomas of all thicknesses appearing in the cancer registry. Indeed, in a study verifying data from 3 regional Dutch cancer registries from 1990 it was found that the completeness of skin malignancies (excluding basal cell carcinomas) was 92.9% [20] .
However, the proportion of cases not being included in the database would largely depend on histopathology diagnosis, and presumably most of the 7.1% of 'missed' cases would be squamous cell carcinomas. Moreover, an increase in completeness of the registry above the 92.9% is unlikely to result in EAPCs as strong as observed among all thickness categories in our study.
Although awareness of potential harmful effects of sun exposure has increased in the Netherlands in recent years [21] , incidence rates of melanoma have not stabilized and are expected to rise even further [22] . Incidence rates were increasing most steeply in older patients (>65 years The largest incidence rates and mortality rates were observed in older patients. Therefore, future secondary prevention campaigns should aim to increase awareness in this high risk group. Although it might be difficult to reach specific subgroup of patients, targeted secondary prevention campaigns may be possible [23] .
Trends in survival
The survival of Dutch melanoma patients has been described for three geographic regions in the Netherlands [24] [25] , showing that survival rates of females were significantly better and independent of patient's demographics and classical melanoma characteristics. We observed an increase in 10-year relative survival for both sexes over time. In most European countries, the 5-year relative survival improved as well, with a relative increase varying from 1 to 30% [26] . In the observed time period no major improvements in the treatment of melanoma have been introduced. The improvements in relative survival may partly have been caused by increased awareness and earlier detection, which artificially prolongs survival time leading to a lead time bias in the analysis [27] . Our multivariate survival analyses were adjusted for follow-up time of each patient to correct for lead time bias as much as possible. Observed changes in distribution of melanoma thickness, histological subtype and other prognostic factors could have caused the change in survival. Multivariate analysis on survival showed that period of diagnosis decreased relative survival, independent of changes in distribution of all known prognostic factors over time. This result might be caused by the introduction of the sentinel lymph node procedure for melanoma patients in 1992, although the effect on survival is still unclear and under evaluation [28] . Another possibility is that dermatologist and pathologists in more recent periods became more cautious and classified slightly atypical pigmented lesions more often as malignant melanomas [7] . This diagnostic drift leads to a bias of prolonged survival times in the more recent periods.
It is expected that survival may improve even further in the future, particularly for advanced disease, because new promising therapies are currently tested in clinical trials [29] . These therapies include B-RAF inhibitors and cytotoxic T-Lymphocyte Antigen-4 (CTLA-4)
inhibitors. B-RAF is part of the mitogen-activated protein kinase (MAPK) pathway and is mutated in approximately 60% of all melanomas [30] . Increased expression of CTLA-4
downregulates the immune response [31] . By inhibiting CTLA-4 the naturally occurring immune responses to tumor cells can be enhanced. Recently a phase III trial on ipilimumab was published, showing improved overall survival in patients with metastatic melanoma [32] .
Trends in mortality
We observed increased mortality rates, which is in contrast with findings in most other countries, where mortality rates remain stable over the years [14] [15] 33] . As melanoma thickness is a strong predictor for disease progression, the observed increase in thick melanomas could have been the cause of the increased mortality rates [34] [35] [36] . In other European countries, like England, France, Italy, Sweden and Poland, mortality rates increased as well [26, 37] . In our data mortality rates did not increase as rapidly as incidence rates, which could have been caused by the improved survival of melanoma patients. Incidence rates of patients diagnosed with metastatic melanomas did not increase over time, but mortality rates did increase during the study period and do not seem to stabilize [ Figure 3 ].
This indicates that a subgroup of melanomas without distant metastasis at diagnosis metastasize over time leading to death.
Increased incidence rates accompanied by increased mortality rates suggest a true increase in the amount of melanomas, rather then a potential overdiagnosis [6] [7] 38] . We therefore state that the observed increase in incidence reflects a real increase of melanoma patients in the Netherlands, rather than an artifact which have been caused by diagnostic drift.
Conclusion
We observed increased incidence rates of melanoma in the Netherlands since 1989. This was due to the increase of thin as well as thick melanomas, which is a worrying trend as melanoma thickness is a strong predictor for prognosis [34] [35] [36] . The increase in incidence was accompanied by an increase in mortality. Survival improved over time independent of the distribution of all known prognostic factors. This pattern points at a real melanoma epidemic in the Netherlands. To improve survival and decrease incidence and mortality rates in the future, efforts should be made to increase primary and secondary prevention of melanoma.
Primary prevention campaigns should aim at parents to protect their children from sunburns in childhood and adolescence. Secondary prevention campaigns should include older and male patients to increase awareness of melanoma. 
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